Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/1/2020
SIETES contiene 92882 citas

 
 
 1 a 20 de 22666 siguiente >>
Presentar resultados
Seleccionar todas
2.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020;395:11 de enero. [Ref.ID 103504]
3. Cita con resumen
Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial . Circulation 2020;141:enero. [Ref.ID 103503]
4. Cita con resumen
Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLOS Medicine 0:9 de diciembre. [Ref.ID 103502]
5. Cita con resumen
Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, et al.. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020;395:4 de enero. [Ref.ID 103501]
6.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for adults with migraine. U.S. Food and Drug Administration 2019:23 de diciembre. [Ref.ID 103240]
7. Cita con resumen
Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction 2019;114:septiembre. [Ref.ID 103238]
8. Cita con resumen
Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]
9. Cita con resumen
Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Corne CE, Cooper AD, Criner GJ, Curtis JL, Han MK, Hatipoglu U, Helgeson ES, JAIN VV, Kalhan R, Kaminskiy D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE, for the BLOCK COPD. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med 2019;381:12 de diciembre. [Ref.ID 103230]
10.Enlace a cita original Cita con resumen
Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Texeira J. Effects of benzodiazepines administration on identification of facial expressions of emotion: a meta-analysis. Psychopharmacology (Berl) 2019:noviermbre. [Ref.ID 103227]
11. Cita con resumen
Simó Miñana J. Guerras médicas: a propósito del ensayo EXCEL . Salud, dinero y atención primaria 2019:15 de diciembre. [Ref.ID 103225]
12. Cita con resumen
Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. “Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ 2019;367:12 de diciembre. [Ref.ID 103224]
13. Cita con resumen
Blanco-Silvente L, Castells X, Garre-Olmo J, Vilalta-Franch J, Saez M, Barceló MA, Capellà D. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103212]
14. Cita con resumen
Shah R, Khan B, Latham SB, Khan SA, Rao SB. A meta-analysis of aspirin for the primary prevention of cardiovascular diseases in the context of contemporary preventive strategies. Am J Med 2019:31 de mayo. [Ref.ID 103205]
15. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
16. Cita con resumen
Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]
18.Enlace a cita original Cita con resumen
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019:19 de septiembre. [Ref.ID 103194]
19. Cita con resumen
Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:1. [Ref.ID 103193]
20.Enlace a cita original Cita con resumen
Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]
Seleccionar todas
 
 1 a 20 de 22666 siguiente >>